GlassScriptPhysician profile
Hassan Zeb
NPI 1114302650
$13,256.80
in general payments reported to CMS, 2019-2025
38 companies · $4,469 in 2025
The $4,469 reported for 2025 was more than what 87% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $26.65 · 2021: $556 · 2022: $2,425 · 2023: $3,050 · 2024: $2,285 · 2025: $4,469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,011 · Travel and Lodging: $1,417 · Education: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,011.10 |
| Travel and Lodging | $1,417.15 |
| Education | $375.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,773.72 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Intuitive Surgical, INC. | $1,762.76 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,753.82 | 2021-2025 | Fasenra, Tezspire, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,461.71 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $811.19 | 2022-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $741.29 | 2022-2025 | Opsumit, Uptravi |
| United Therapeutics Corporation | $665.96 | 2021-2025 | Tyvaso, Tyvaso |
| Genzyme Corporation | $604.94 | 2022-2025 | |
| Grifols USA, LLC | $402.20 | 2021-2025 | Prolastin-C Liquid |
| Baxter Healthcare | $382.20 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System, Hillrom - Monarch Airway Clearance System |
| Mallinckrodt Hospital Products INC. | $342.96 | 2021-2025 | Acthar |
| Electromed, INC. | $309.05 | 2019-2025 | Smartvest |
| Mylan Specialty L.P. | $273.35 | 2021-2023 | Yupelri |
| Sanofi-Aventis U.S. LLC | $238.97 | 2022-2025 | |
| Genentech USA, INC. | $201.14 | 2022-2025 | Xolair |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $183.93 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Insmed, INC. | $153.43 | 2025 | Arikayce, Brinsupri |
| Abbvie INC. | $138.67 | 2022-2025 | Avycaz |
| Amgen INC. | $123.56 | 2021-2025 | Tezspire |
| Steris Corporation | $123.20 | 2023 | |
| Viatris Specialty LLC | $115.34 | 2025 | Yupelri |
| Philips North America LLC | $96.11 | 2022-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Pfizer INC. | $81.43 | 2022-2025 | |
| Verona Pharma, INC. | $77.17 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $69.83 | 2022-2024 | Glassia |
| Merck Sharp & Dohme LLC | $65.42 | 2023-2025 | Zerbaxa, Dificid, Recarbrio |
| Melinta Therapeutics, LLC | $51.76 | 2024 | Rezzayo, Orbactiv, Kimyrsa |
| Janssen Pharmaceuticals, INC | $47.06 | 2022-2024 | Xarelto |
| Pulmonx Corporation | $29.20 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Zoll Circulation INC | $26.65 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.76 | 2022 | |
| Theratechnologies INC. | $24.74 | 2024 | Trogarzo, Egrifta |
| Ani Pharmaceuticals, INC. | $24.24 | 2022 | |
| Kedrion Biopharma, INC. | $18.15 | 2024 | Rhogam Ultra-Filtered Plus, Albuked, Koate |
| Vifor Pharma, INC. | $15.78 | 2024 | Zemaira |
| Advanced Respiratory, INC | $14.68 | 2021 | |
| Nevro Corp. | $13.25 | 2023 | Senza |
| Sandoz INC. | $13.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hassan Zeb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.